ReviewCurrent obesity reports2025
The Efficacy of Various Weight Loss Strategies in Alleviating Polycystic Ovary Syndrome.
Review in Current obesity reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bariatric surgery as a treatment of polycystic ovary syndrome: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- The central role of hyperandrogenism in driving metabolic dysfunction in polycystic ovary syndrome: from pathophysiological mechanisms to targeted therapies.Journal of ovarian research · 2026Review
- Gut microbiota and polyendocrine metabolic ovarian syndrome: an integrated gut-metabolism-endocrine-ovary axis.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- Implications of Metabolic Bariatric Surgery on Reproductive Health.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purpose of reviewPolycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in women of reproductive age, with its severity often exacerbated by obesity. The bidirectional relationship between PCOS and obesity contributes to a self-reinforcing and deleterious cycle. This review evaluates the effects of various weight loss interventions on reproductive, hormonal, and metabolic outcomes in overweight or obese women with PCOS. The objective is to provide evidence-based guidance for clinically relevant weight management strategies in this population. RECENT
findingsLifestyle modification is the first-line intervention for polycystic ovary syndrome (PCOS). High-intensity interval training (HIIT) has demonstrated potential in improving insulin resistance (IR) in affected women. Time-restricted feeding (TRF) may also improve hyperandrogenism, menstrual irregularities, and IR. The ketogenic diet (KD) has shown beneficial effects on both reproductive and metabolic outcomes. Among pharmacological therapies, glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly when combined with metformin, have exhibited notable efficacy in managing hyperandrogenism and menstrual disturbances. Bariatric surgery appears to be more effective than conventional pharmacologic treatments for PCOS; however, data on its mechanisms and direct comparisons with GLP-1RAs remain limited. Weight loss interventions exert differential effects on PCOS-related symptoms. Future studies should focus on optimizing combination strategies to enhance treatment efficacy. Currently, evidence on the impact of these interventions on pregnancy rates and long-term reproductive outcomes in overweight or obese women with PCOS is limited. In addition, the absence of systematic, head-to-head comparisons across different weight loss modalities underscores the need for well-designed comparative trials.
Indexed as
Identifiers
40580384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.